Avalo Therapeutics (AVTX) Expected to Announce Earnings on Friday

Avalo Therapeutics (NASDAQ:AVTX) will likely be releasing its earnings data before the market opens on Friday, April 4th. Analysts expect Avalo Therapeutics to post earnings of $0.58 per share for the quarter.

Avalo Therapeutics Stock Performance

AVTX stock opened at $8.73 on Friday. Avalo Therapeutics has a fifty-two week low of $5.99 and a fifty-two week high of $34.46. The business has a 50 day moving average price of $7.59 and a 200 day moving average price of $9.13.

Analysts Set New Price Targets

A number of research firms have commented on AVTX. Wedbush reissued an “outperform” rating and issued a $18.00 target price on shares of Avalo Therapeutics in a report on Thursday, March 20th. Stifel Nicolaus assumed coverage on Avalo Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $36.00 price target on the stock. Piper Sandler initiated coverage on Avalo Therapeutics in a report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price target for the company. Jefferies Financial Group started coverage on shares of Avalo Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $23.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $33.00.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.